Cited by 734Colorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

Open access

Di Fiore, F, Blanchard, F, Charbonnier, F, Le Pessot, F, Lamy, A, Galais, M P, Bastit, L, Killian, A, Sesboüé, R, Tuech, J J, Queuniet, A M, Paillot, B, Sabourin, J C, Michot, F, Michel, P, Frebourg, T·2007·British Journal of Cancer

DOI 10.1038/sj.bjc.6603685PMC PMC2360149

Open this paper in CoChat — free account Open PDF

Abstract

The predictive value of KRAS mutation in metastatic colorectal cancer (MCRC) patients treated with cetuximab plus chemotherapy has recently been suggested. In our study, 59 patients with a chemotherapy-refractory MCRC treated with cetuximab plus chemotherapy were included and clinical response was evaluated according to response evaluation criteria in solid tumours (RECIST). Tumours were screened for KRAS mutations using first direct sequencing, then two sensitive methods based on SNaPshot and PCR-ligase chain reaction (LCR) assays. Clinical response was evaluated according to gene mutations using the Fisher exact test. Times to progression (TTP) were calculated using the Kaplan-Meier method and compared with log-rank test. A KRAS mutation was detected in 22 out of 59 tumours and, in six cases, was missed by sequencing analysis but detected using the SNaPshot and PCR-LCR assays. Remarkably, no KRAS mutation was found in the 12 patients with clinical response. KRAS mutation was associated with disease progression (P=0.0005) and TTP was significantly decreased in mutated KRAS patients (3 vs 5.5 months, P=0.015). Our study confirms that KRAS mutation is highly predictive of a non-response to cetuximab plus chemotherapy in MCRC and highlights the need to use sensitive molecular methods, such as SNaPshot or PCR-LCR assays, to ensure an efficient mutation detection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6603685

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
Kabbinavar, F. F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Liebérman, G., Griffing, S., & Bergsland, E. K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,711
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,080
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
LigAmp for sensitive detection of single-nucleotide differences
Shi, C., Eshleman, S. H., Jones, D. C., Fukushima, N., Li, H., Parker, A. R., Yeo, C. J., Hruban, R. H., Goggins, M., & Eshleman, J. R. (2004) · Nature Methods · doi:10.1038/nmeth713 · Cited by 127

Flagged first, then by citations

Show all 12 references

Sorted by citations

Items 501–600 of 734

Pattern Recognition of p53 and KRAS in Whole Blood Samples
Staden, R. S., Ilie‐Mihai, R., Gugoaşă, L. A., & Stanciu‐Găvan, C. (2019) · Journal of The Electrochemical Society · doi:10.1149/2.0201904jes · Cited by 8
Designing Pharmacogenomic Studies to be Fit for Purpose
Burns, D. K., Hughes, A. R., Power, A., Wang, S., & Patterson, S. D. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.140 · Cited by 8
Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer
Hebbar, M., Fiore, F. D., Conroy, T., Giraud, C., Gasnault, L., Fournier, C., Péreira, R., Bouché, O., Fournier, P., Deligny, N., et al. (2007) · Oncology · doi:10.1159/000127385 · Cited by 8
Self-citation
Update on Novel Strategies to Optimize Cetuximab Therapy in Patients with Metastatic Colorectal Cancer
Macarulla, T. M., Ramos, F. J., Élez, E., Capdevila, J., Peralta, S., & Tabernero, J. M. (2008) · Clinical Colorectal Cancer · doi:10.3816/ccc.2008.n.039 · Cited by 7
Cetuximab-induced insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells
Li, X., Xu, L., Li, H., Zhao, L., Luo, Y., Zhu, Z., Liu, Y., & Qu, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3245 · Cited by 8
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment
Soeda, H., Shimodaira, H., Watanabe, M., SUZUKI, T., Gamo, M., Takahashi, M., Komine, K., Kato, S., & Ishioka, C. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.254 · Cited by 8
XELOX in colorectal cancer: a convenient option for the future?
Lindsay, C. R., & Cassidy, J. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.10.90 · Cited by 8
Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Loupakis, F., Cremolini, C., Fontanini, G., Stasi, I., Salvatore, L., & Falcone, A. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009348984 · Cited by 8
Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers
Li, X., Duan, Y., Qiao, C., Zhou, T., Yu, M., Geng, J., Feng, J., Shen, B., Lv, M., & Li, Y. (2015) · Technology in Cancer Research & Treatment · doi:10.1177/1533034615588422 · Cited by 8
The area between ROC curves, a non‐parametric method to evaluate a biomarker for patient treatment selection
Blangero, Y., Rabilloud, M., Laurent‐Puig, P., Malicot, K. L., Lepage, C., Écochard, R., Taı̈eb, J., & Subtil, F. (2020) · Biometrical Journal · doi:10.1002/bimj.201900171 · Cited by 8
Cancers colorectaux avant et après les biothérapies : une révolution dans la prise en charge des patients ?
Rougier, P. R., & Mitry, E. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.07.019 · Cited by 8
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
Lockhart, C. (2009) · OncoTargets and Therapy · doi:10.2147/ott.s3849 · Cited by 7
Molecular differences in the KRAS gene mutation between a primary tumor and related metastatic sites - case report and a literature review.
Kosakowska, E. A., Stec, R., Charkiewicz, R., Skoczek, M., & Chyczewski, L. (2011) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-010-0078-z · Cited by 7
Development and Analytical Validation of a DNA Dual-Strand Approach for the US Food and Drug Administration–Approved Next-Generation Sequencing–Based Praxis Extended RAS Panel for Metastatic Colorectal Cancer Samples
Udar, N., Iyer, A., Porter, M., Haigis, R. W., Smith, S. E., Dhillon, S., Meier, K. M., Ward, D., Lü, J., Wenz, P., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.09.009 · Cited by 7
Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients
Tian, S., Wang, F., Lu, S., Wu, R., & Chen, G. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1843662 · Cited by 7
A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study
Matsumura, M., Hasegawa, K., Oba, M., Yamaguchi, K., Uetake, H., Yoshino, T., Morita, S., Takahashi, K., Unno, M., Shimada, Y., et al. (2022) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-022-02434-7 · Cited by 7
Review: Medical treatment of advanced colorectal cancer in 2009
Grothey, A. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009343302 · Cited by 7
PCR-Based Assays versus Direct Sequencing for Evaluating the Effect of KRAS Status on Anti-EGFR Treatment Response in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
Shan, L., Li, M., Ma, J., & Zhang, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107926 · Cited by 7
Impact of cetuximab in current treatment of metastatic colorectal cancer
Sotelo, M. J., Valera, J. S., & Díaz‐Rubio, E. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.883376 · Cited by 8
Combined Assessment of Endothelial Growth Factor Receptor Dual Color In Situ Hybridization and Immunohistochemistry with Downstream Gene Mutations in Prediction of Response to the Anti-EGFR Therapy for Patients with Metastatic Colorectal Cancer
Takahashi, N., Yamada, Y., Taniguchi, H., Honma, Y., Iwasa, S., Kato, K., Hamaguchi, T., & Shimada, Y. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.05.004 · Cited by 7
KRAS mutation screening by chip-based DNA hybridization – a further step towards personalized oncology
Steinbach, C., Steinbrücker, C., Pollok, S., Walther, K., Clement, J. H., Chen, Y., Petersen, I., Cialla‐May, D., Weber, K., & Popp, J. (2015) · The Analyst · doi:10.1039/c4an02086c · Cited by 7
Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2
Boeckx, N., Peeters, M., Camp, G. V., Pauwels, P., de Beeck, K. O., & Deschoolmeester, V. (2015) · Drugs · doi:10.1007/s40265-015-0459-x · Cited by 7
Ionic strength-controlled hybridization and stability of hybrids of KRAS DNA single-nucleotides: A surface plasmon resonance study
Giamblanco, N., Petralia, S., Sabrina Conoci, A., Messineo, C., & Marletta, G. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.06.021 · Cited by 7
From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development
Doroshow, D. B., & Doroshow, J. H. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000386 · Cited by 9
Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3
Wang, W., Zhang, Y., Lv, M., Feng, J., Peng, H., Geng, J., Zhou, L., Zhou, T., Li, X., Shen, B., et al. (2014) · Journal of Ovarian Research · doi:10.1186/s13048-014-0103-5 · Cited by 7
KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
Lopez‐Crapez, E., Mineur, L., Emptas, H., & Lamy, P. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605582 · Cited by 7
What Is Different in the Population of the Brazilian Amazon Region so that They Have a Low Frequency of KRAS Gene Mutations
de Carvalho, L. E. W., Sarraf, J. S., Oliveira, A. C. M., Neto, N. D. B., Câmara, T. F., Fonseca, F. L. A., & Adami, F. (2017) · Case Reports in Oncology · doi:10.1159/000479733 · Cited by 6
Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer.
Tsoukalas, N., Tzovaras, A. A., Tolia, M., Kostakis, I. D., Papakostidi, A., Pistamaltzian, N. F., & Ardavanis, A. (2012) · PubMed · Cited by 6
Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience
Welland, S., deCastro, T., Bathon, M., Wirth, T. C., Reineke‐Plaaß, T., Saborowski, M., Lehmann, U., Saborowski, A. L., & Vogel, A. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03774-5 · Cited by 7
MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS-mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy
Li, G., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00024-9 · Cited by 7
Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors
Schnabel, C. A., & Erlander, M. G. (2012) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2012.704363 · Cited by 6
Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients.
Pfeiffer, P., Qvortrup, C., & Bjerregaard, J. K. (2009) · PubMed Central · Cited by 6
Emerging Technologies for Improved Stratification of Cancer Patients
Lamlertthon, W., Hayward, M. C., & Hayes, D. N. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823bd1f8 · Cited by 6
RETRACTED ARTICLE: 5-Fluorouracil Trapping in a Porous Ba(II)-organic Framework: Drug Delivery and Anti-thyroid Cancer Activity Evaluation
Zhang, Q. J., Zhao, J., Li, Y., Wu, X. Y., Ma, L. L., & Ding, Z. (2020) · Russian Journal of Coordination Chemistry · doi:10.1134/s1070328420080072 · Cited by 6
Retracted
The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.
Kloth, D. D., Iacovelli, L. M., Arbuckle, R. B., & McIntosh, A. C. (2010) · Europe PMC (PubMed Central) · Cited by 6
Individualization of therapy for colorectal cancer based on clinical and molecular parameters.
Pohl, A., & Lenz, H. (2008) · PubMed Central · Cited by 6
KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents
Bekaii‐Saab, T. (2009) · Clinical Colorectal Cancer · doi:10.3816/ccc.2009.n.022 · Cited by 6
Comparison of KRAS Genotype: Therascreen Assay vs. LNA-Mediated qPCR Clamping Assay
Chang, S.-C., Denne, J. S., Zhao, L., Horak, C. E., Green, G., Khambata‐Ford, S., Bray, C., Celik, I., Cutsem, E. V., & Harbison, C. T. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.05.001 · Cited by 5
Adaptive responses to antibody based therapy
Rodems, T. S., Iida, M., Brand, T. M., Pearson, H. E., Orbuch, R. A., Flanigan, B. G., & Wheeler, D. L. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.01.001 · Cited by 6
Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?
Allard, M., Saffroy, R., de la Maisonneuve, P. B., Ricca, L., Bosselut, N., Hamelin, J., Lecorché, E., Bejarano, M., Innominato, P. F., Sebagh, M., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0346-5 · Cited by 5
Pharmacogenomics of Cetuximab in Metastatic Colorectal Carcinoma
Silvestris, N., Vincenzi, B., Brunetti, A. E., Loupakis, F., Dell’Aquila, E., Russo, A. D., Scartozzi, M., Giampieri, R., Cascinu, S., Lorusso, V., et al. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.124 · Cited by 5
Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan
Saeki, H., Emi, Y., Kumashiro, R., Otsu, H., Kawano, H., Ando, K., Ida, S., Kimura, Y., Tokunaga, E., Oki, E., et al. (2013) · Surgery Today · doi:10.1007/s00595-013-0716-0 · Cited by 5
First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
Tonini, G. (2009) · OncoTargets and Therapy · doi:10.2147/ott.s3465 · Cited by 5
Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer
Lv, N., Lin, S., Xie, Z., Tang, J., Ge, Q., Wu, M., Xie, X., Xie, X., & Wei, W. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.01.004 · Cited by 5
Role of β4 Integrin in HER-3 -negative, K-RAS Wild-Type Metastatic Colorectal Tumors Receiving Cetuximab
Scartozzi, M., Giampieri, R., Loretelli, C., Mandolesi, A., Prete, M. D., Biagetti, S., Alfonsi, S., Faloppi, L., Bianconi, M., Bittoni, A., et al. (2013) · Future Oncology · doi:10.2217/fon.13.72 · Cited by 5
Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer
Kim, D., Hong, Y. S., Kim, J. E., Kim, K., Lee, J., Chun, S., Kim, J., Jang, S. J., & Kim, T. W. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.069 · Cited by 5
Theranostic of biopharmaceuticals
Chaigne, B., & Watier, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.035 · Cited by 5
Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue
Liu, Y., Li, L., Tian, Y., Zhu, X. D., Sun, A., Sun, Y., Qiao, Y., Qi, X., & Wang, T. (2020) · Biotechnic & Histochemistry · doi:10.1080/10520295.2020.1810775 · Cited by 5
Colon and Rectum
(2010) · Springer eBooks · doi:10.1007/978-0-387-88443-1_14 · Cited by 5
What oncologists need and require from nuclear medicine
Pantaleo, M. A., Fanti, S., Nannini, M., Boschi, S., Nanni, C., Maleddu, A., Rubello, D., & Biasco, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0825-y · Cited by 5
Current status of antivascular therapy and targeted treatment in the clinic
Dahl, O., Borkamo, E. D., & Fluge, Ø. (2008) · International Journal of Hyperthermia · doi:10.1080/02656730701824406 · Cited by 5
Second‐line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild‐type KRAS
Hong, Y. S., Kim, H. J., Park, S., Kim, K., Lee, J., Park, J., Kim, J. H., Lim, S., Yu, C. S., Kim, J. C., et al. (2013) · Cancer Science · doi:10.1111/cas.12098 · Cited by 5
Beyond the KRAS test
Laurent‐Puig, P., Lièvre, A., & Blons, H. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70063-2 · Cited by 6
Genetics Primer for the General Cardiologist
MacRae, C. A. (2011) · Circulation · doi:10.1161/circulationaha.111.018879 · Cited by 5
Predictive Genomic Biomarkers
Kumar, R., & Amado, R. G. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2011_164 · Cited by 4
Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense?
Nannini, M., Pantaleo, M. A., Paterini, P., Piazzi, G., Ceccarelli, C., Rovere, S. L., Maleddu, A., & Biasco, G. (2010) · Colorectal Disease · doi:10.1111/j.1463-1318.2010.02212.x · Cited by 4
Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer
Toumazis, I., Kurt, M., Toumazi, A., Karacosta, L. G., & Kwon, C. (2017) · MDM Policy & Practice · doi:10.1177/2381468317729650 · Cited by 4
Neo‐Antigen‐Reactive T Cells Immunotherapy for Colorectal Cancer: A More Personalized Cancer Therapy Approach
Chen, G., Kong, D., & Lin, Y. (2023) · Global Challenges · doi:10.1002/gch2.202200186 · Cited by 3
First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?
Airoldi, M., Bartolini, M., Fazio, R., Farinatti, S., Daprà, V., Santoro, A., & Puccini, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01601-x · Cited by 5
Clinical Implications and Quality Assurance of Molecular Testing for EGFR-Targeting Agents in Colorectal Cancer
Vecchione, L., Saridaki, Z., & Tejpar, S. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0112-3 · Cited by 4
Optimal approach to potentially resectable liver metastases from colorectal cancer
Falcone, A., Fornaro, L., Loupakis, F., Masi, G., & Vasile, E. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.10.1533 · Cited by 4
Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients
Santini, D., Pantano, F., Vincenzi, B., Loupakis, F., Caraglia, M., Falcone, A., & Tonini, G. (2008) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2008.06.008 · Cited by 4
Cetuximab efficacy in patients treated routinely in university hospitals
Bachet, J., Afchain, P., Fermanian, C., Bouchahda, M., Mitry, E., Landi, B., André, T., Lièvre, A., Louvet, C., Aegerter, P., et al. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)78302-1 · Cited by 4
How to integrate biologicals in the continuum of care
Venugopal, B., & Cassidy, J. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70017-6 · Cited by 4
BTH1677 in combination with cetuximab with and without irinotecan in patients with advanced metastatic colorectal cancer
Cornelio, G. H., Tamayo, M. E., Flores, M. L., Bautista, J. B., TIOLECO, P. S., Gargano, M. A., Kurman, M. R., Walsh, R. M., Béliveau, M., Marier, J., et al. (2016) · Colorectal Cancer · doi:10.2217/crc-2016-0010 · Cited by 4
Evolution of RAS Testing Over Time: Factors Influencing Mutation Rates in Metastatic Colorectal Cancer Patients
Dufraing, K., Keppens, C., Tack, V., Siebers, A. G., Kafatos, G., Dube, S., Demonty, G., Lowe, K. A., Kroeze, L. I., Ligtenberg, M. J. L., et al. (2020) · Colorectal Cancer · doi:10.2217/crc-2019-0013 · Cited by 4
Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
Ulivi, P., Passardi, A., Marisi, G., Chiadini, E., Molinari, C., Canale, M., Pasini, L., Ferroni, F., Frassineti, G. L., Bartolini, G., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.745701 · Cited by 5
Identification of hub genes related to CD4+ memory T cell infiltration with gene co-expression network predicts prognosis and immunotherapy effect in colon adenocarcinoma
Tang, L., Yu, S., Zhang, Q., Cai, Y., Li, W., Yao, S., & Cheng, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.915282 · Cited by 4
Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report
Soueidy, C., Skaff, S., Stéphan, F., & Kattan, J. G. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001312 · Cited by 4
Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer
Freeman, D. J. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2039 · Cited by 4
EGFR/HER1 : histoire d’une cible thérapeutique
Viel, E., Curtit, E., Mansi, L., & Vignot, S. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2011.1385 · Cited by 4
Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab
Barbier, A., Dômont, J., Magné, N., Goldmard, J.-L., Genestie, C., Hannoun, C., Vaillant, J., Bellanger, A., Khayat, D., Capron, F., et al. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1033 · Cited by 4
Drug Approval Challenges in the Age of Personalized Cancer Treatment
Schilsky, R. L. (2011) · Personalized Medicine · doi:10.2217/pme.11.74 · Cited by 4
KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
Hebbar, M., Fournier, P., & ROMANO, O. (2009) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2009.01134.x · Cited by 4
Novel multiple, monoallelic KRAS mutations at codon 12 and 13
Keller, G., Geist, B., Slotta‐Huspenina, J., Langer, R., Nagl, F., Fend, F., Höfler, H., & Perren, A. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24635 · Cited by 4
Current Status of Chemotherapy for Advanced Colorectal Cancer in Japan
Yamada, Y. (2008) · Clinical Colorectal Cancer · doi:10.3816/ccc.2008.n.003 · Cited by 4
Advocacy in Personalized Medicine: A Developing Strength in A Complex Space
Miller, I., Pothier, K. C., & Dunn, M. (2010) · Personalized Medicine · doi:10.2217/pme.10.2 · Cited by 4
Highly Sensitive KRAS Mutation Detection from Formalin-Fixed Paraffin-Embedded Biopsies and Circulating Tumour Cells Using Wild-Type Blocking Polymerase Chain Reaction and Sanger Sequencing
Huang, M. M. C., Leong, S. M., Chua, H. W., Tucker, S. J., Cheong, W. C., Chiu, L., Li, M., & Koay, E. S.-C. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0098-z · Cited by 4
Detection of KRAS and BRAF mutations in advanced colorectal cancer by allele-specific single-base primer extension
Balschun, K., Wenke, A., Röcken, C., & Haag, J. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.75 · Cited by 4
Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS
Shitara, K., Yokota, T., Takahari, D., Shibata, T., Ura, T., Komatsu, Y., Yuki, S., Yoshida, M., Takiuchi, H., Utsunomiya, S., et al. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq026 · Cited by 4
Can Epidermal Growth Factor Receptor–Fluorescent in Situ Hybridization Predict Clinical Benefit From Cetuximab Treatment in Patients With Non–Small-Cell Lung Cancer?
Takano, T., Ota, S., Hori, A., Seki, N., & Eguchi, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0105 · Cited by 4
Molecular analysis and clinicopathologic features of advanced colorectal cancer in Algerian patients
(2020) · doi:10.5348/t09-2016-4-oa-1 · Cited by 4
KRAS-mutant colorectal cancer cell lines cause a prothrombotic state through the upregulation of thrombin: experimental study
Xu, D., Liao, C., & Tan, J. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001645 · Cited by 3
Detection of KRAS Mutations in Triple-negative Breast Cancers by Polymerase Chain Reaction
Vodithala, S., & Bhake, A. S. (2024) · Journal of Datta Meghe Institute of Medical Sciences University · doi:10.4103/jdmimsu.jdmimsu_703_23 · Cited by 3
EGF/EGFR signaling axis is a significant regulator of the proteasome expression and activity in colon cancer cells
Ellina, M.-I., Bouris, P., Kletsas, D., Aletras, A. J., & Karamanos, N. K. (2014) · ScienceOpen Research · doi:10.14293/a2199-1006.01.sor-life.ac0e6.v1 · Cited by 3
Az epidermális növekedési faktor receptorát célzó terápiák RAS paradoxona vastag- és végbélrákban
Tímár, J., & Láng, I. (2008) · Magyar Onkológia · doi:10.1556/monkol.52.2008.2.7 · Cited by 3
A Real-Life Experience Using Panitumumab in Chemo-Refractory Metastatic Colorectal Cancer Patients: A Retrospective Analysis at the Jewish General Hospital, 2009–2012
Mamo, A., Nogueira, M. C., Batist, G., Palumbo, M. O., Panasci, L., Ferrario, C., Chaudhury, P. K., Metrakos, P. P., & Kavan, P. (2013) · Current Oncology · doi:10.3747/co.20.1271 · Cited by 3
Toward an Individualizing Therapy for Colorectal Cancer: The Example of the Anti-EGFR Monoclonal Antibodies
Lièvre, A., & Laurent‐Puig, P. (2009) · Personalized Medicine · doi:10.2217/17410541.6.2.145 · Cited by 3
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Chan, W., Lee, V. H.-F., Siu, W., Ho, P. Y. P., Liu, R. K. Y., & Leung, T. (2014) · South Asian Journal of Cancer · doi:10.4103/2278-330x.136802 · Cited by 3
Cancer colorectaux métastatiques et thérapies ciblées anti-EGFR
Viret, F., & Gonçalvès, A. (2009) · médecine/sciences · doi:10.1051/medsci/2009251s13 · Cited by 3
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
Ciardiello, F., Tejpar, S., & Papamichael, D. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0129-6 · Cited by 4
Genotyping by Induced Förster Resonance Energy Transfer (iFRET) Mechanism and Simultaneous Mutation Scanning
Masojć, B., Górski, B., van de Wetering, T., Dębniak, T., Cybulski, C., Jakubowska, A., Mędrek, K., Rudnicka, H., Dwight, Z., & Lubiński, J. (2013) · Human Mutation · doi:10.1002/humu.22281 · Cited by 3
Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
Mileshkin, L., Shah, B., & Michael, M. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/838509 · Cited by 3
Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer
Jackson, C., & Cunningham, D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.021 · Cited by 3
KRAS Codons 12 and 13 Mutation Analysis: A Comparative Study between Direct Sequencing and a New Sensitive Real-Time PCR Assay
Marzinotto, S., Sessa, F., Franzoni, A., Anselmi, A., Gastaldo, L. R., Mason, S., Damante, G., Beltrami, C. A., & Mariuzzi, L. (2011) · Sequencing · doi:10.1155/2011/895709 · Cited by 4
DROPLET-BASED MICROFLUIDICS FOR THE QUANTITATIVE DETECTION OF RARE MUTATIONS
Pekin, D., Skhiri, Y., Corre, L., Mažutis, L., Salem, C. B., Griffiths, A. D., Laurent‐Puig, P., & Taly, V. (2010) · Cited by 3
Surgical Treatment of Metastases and its Impact on Prognosis in Patients with Metastatic Colorectal Carcinoma
Ševčíková, K., Usakova, V., Bartošová, Z., Sabol, M., Ondrušová, M., Ondruš, D., & Spanik, S. (2014) · Klinicka onkologie · doi:10.14735/amko201438 · Cited by 3
Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience.
Daoud, M. A., Aboelnaga, E. M., & Mohamed, W. M. (2016) · PubMed Central · doi:10.28092/j.issn.2095-3941.2015.0009 · Cited by 3
Hybridization-Induced Aggregation Technology for Practical Clinical Testing
Sloane, H. S., Landers, J. P., & Kelly, K. A. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.02.004 · Cited by 3
Clinical benefit of cetuximab and prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analysis.
Cvetanović, A., Vrbić, S., Filipovic, S., Pejčić, I., Milenković, D., Živković, N., Kostić, M. S., & Petković, I. (2014) · PubMed · Cited by 3

Authors: Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., Queuniet, A. M., Paillot, B., Sabourin, J. C., Michot, F., Michel, P., & Frebourg, T.
Affiliations: Centre Hospitalier Universitaire de Rouen (FR)
Inserm (FR)
Centre Hospitalier Universitaire de Caen Normandie (FR)
ORCID: Galais, M P
Killian, A
Tuech, J J
Sabourin, J C
Michel, P
Venue: British Journal of Cancer
Publisher: Springer Science and Business Media LLC
Published: 2007-03-20
Volume: 96
Issue: 8
Pages: 1166-1169
ISSN: 0007-0920 (ISSN-L)
1532-1827
DOI: 10.1038/sj.bjc.6603685
PMC: PMC2360149
OpenAlex: W1999250974
Cited by: 734
References: 12
Citations by year: 2025: 6 · 2024: 6 · 2023: 10 · 2022: 10 · 2021: 8 · 2020: 15 · 2019: 14 · 2018: 14 · 2017: 21 · 2016: 30 · 2015: 33 · 2014: 54 · 2013: 52 · 2012: 62
FWCI: 51.47
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-sa
www.springer.com/tdm (unspecified)
Locations: British Journal of Cancer (publishedVersion, cc-by-nc-sa)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: Institut National Du Cancer
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: KRAS mutation, metastatic colorectal cancer, cetuximab, anti-EGFR therapy, predictive biomarkers, chemotherapy-refractory cancer, SNaPshot assay, mutation detection sensitivity, time to progression, clinical response
MeSH terms: Cetuximab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Polymerase Chain Reaction, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks